Janneke Meulenberg, PhD

Janneke Meulenberg has 20+ years of experience in leadership positions in the Biopharmaceutical industry. Prior to joining ORCA, she was a management team member of Amsterdam Molecular Therapeutics  (AMT: now UniQure). She was responsible for successful development of AMT’s lead product Glybera® , the first gene therapy to receive market approval in the Western World. At ID-Lelystad, Janneke headed a world leading R&D team to develop veterinary vaccines in collaboration with Boehringer Ingelheim. She graduated cum laude, received a PhD in Biochemistry and holds an MBA from RSM Erasmus University. She is author of numerous peer-reviewed publications and book chapters, and inventor on several patents.